FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158638287> ?p ?o ?g. }

• W2158638287 endingPage "66" @default.
• W2158638287 startingPage "59" @default.
• W2158638287 abstract "BackgroundAnaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC.Patients and methodsWe identified 121 patients with advanced, ALK-positive NSCLC in the USA, Australia, and Italy. For comparison, we evaluated 266 patients with advanced, ALK-negative, epidermal growth factor receptor (EGFR)-wild-type NSCLC, including 79 with KRAS mutations and 187 with wild-type KRAS (WT/WT/WT). We determined PFS on different pemetrexed regimens.ResultsAmong 70 ALK-positive patients treated with a platinum/pemetrexed regimen, the median PFS (mPFS) was 7.3 months (95% confidence interval (CI) 5.5–9.5). The mPFS of 51 ALK-positive patients treated with single-agent pemetrexed or nonplatinum/pemetrexed combinations was 5.5 months (2.8–9.0). For ALK-negative patients, PFS on all pemetrexed-based regimens was similar to that of ALK-positive patients, except in the specific setting of first-line platinum/pemetrexed where the mPFS was only 4.2 and 5.4 months in KRAS and WT/WT/WT patients, respectively. However, among patients with a never/light-smoking history (0–10 pack-year smoking history) treated with first-line platinum/pemetrexed, there was no difference in PFS between ALK-positive and ALK-negative patients.ConclusionsPFS on pemetrexed or nonplatinum/pemetrexed combinations was similar in ALK-positive and ALK-negative patients. PFS on first-line platinum/pemetrexed may be prolonged in never/light-smoking patients regardless of ALK status." @default.
• W2158638287 created "2016-06-24" @default.
• W2158638287 creator A5001428569 @default.
• W2158638287 creator A5017123525 @default.
• W2158638287 creator A5021171927 @default.
• W2158638287 creator A5027467209 @default.
• W2158638287 creator A5032331306 @default.
• W2158638287 creator A5040093136 @default.
• W2158638287 creator A5045959942 @default.
• W2158638287 creator A5060033755 @default.
• W2158638287 creator A5072389805 @default.
• W2158638287 creator A5079802303 @default.
• W2158638287 creator A5080311196 @default.
• W2158638287 creator A5086249998 @default.
• W2158638287 date "2013-01-01" @default.
• W2158638287 modified "2023-10-18" @default.
• W2158638287 title "Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer" @default.
• W2158638287 cites W1985329793 @default.
• W2158638287 cites W2019539885 @default.
• W2158638287 cites W2031494655 @default.
• W2158638287 cites W2041768451 @default.
• W2158638287 cites W2055402151 @default.
• W2158638287 cites W2065972613 @default.
• W2158638287 cites W2077582166 @default.
• W2158638287 cites W2081095165 @default.
• W2158638287 cites W2093007798 @default.
• W2158638287 cites W2095618958 @default.
• W2158638287 cites W2099725888 @default.
• W2158638287 cites W2101619794 @default.
• W2158638287 cites W2104374250 @default.
• W2158638287 cites W2104830962 @default.
• W2158638287 cites W2106726143 @default.
• W2158638287 cites W2111662961 @default.
• W2158638287 cites W2129360604 @default.
• W2158638287 cites W2132157071 @default.
• W2158638287 cites W2134667653 @default.
• W2158638287 cites W2139110945 @default.
• W2158638287 cites W2139939379 @default.
• W2158638287 cites W2160982674 @default.
• W2158638287 cites W2166084034 @default.
• W2158638287 cites W2418764371 @default.
• W2158638287 doi "https://doi.org/10.1093/annonc/mds242" @default.
• W2158638287 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3525134" @default.
• W2158638287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22887466" @default.
• W2158638287 hasPublicationYear "2013" @default.
• W2158638287 type Work @default.
• W2158638287 sameAs 2158638287 @default.
• W2158638287 citedByCount "97" @default.
• W2158638287 countsByYear W21586382872012 @default.
• W2158638287 countsByYear W21586382872013 @default.
• W2158638287 countsByYear W21586382872014 @default.
• W2158638287 countsByYear W21586382872015 @default.
• W2158638287 countsByYear W21586382872016 @default.
• W2158638287 countsByYear W21586382872017 @default.
• W2158638287 countsByYear W21586382872018 @default.
• W2158638287 countsByYear W21586382872019 @default.
• W2158638287 countsByYear W21586382872020 @default.
• W2158638287 countsByYear W21586382872021 @default.
• W2158638287 countsByYear W21586382872022 @default.
• W2158638287 countsByYear W21586382872023 @default.
• W2158638287 crossrefType "journal-article" @default.
• W2158638287 hasAuthorship W2158638287A5001428569 @default.
• W2158638287 hasAuthorship W2158638287A5017123525 @default.
• W2158638287 hasAuthorship W2158638287A5021171927 @default.
• W2158638287 hasAuthorship W2158638287A5027467209 @default.
• W2158638287 hasAuthorship W2158638287A5032331306 @default.
• W2158638287 hasAuthorship W2158638287A5040093136 @default.
• W2158638287 hasAuthorship W2158638287A5045959942 @default.
• W2158638287 hasAuthorship W2158638287A5060033755 @default.
• W2158638287 hasAuthorship W2158638287A5072389805 @default.
• W2158638287 hasAuthorship W2158638287A5079802303 @default.
• W2158638287 hasAuthorship W2158638287A5080311196 @default.
• W2158638287 hasAuthorship W2158638287A5086249998 @default.
• W2158638287 hasBestOaLocation W21586382871 @default.
• W2158638287 hasConcept C117643217 @default.
• W2158638287 hasConcept C121608353 @default.
• W2158638287 hasConcept C126322002 @default.
• W2158638287 hasConcept C143998085 @default.
• W2158638287 hasConcept C2776232967 @default.
• W2158638287 hasConcept C2776256026 @default.
• W2158638287 hasConcept C2776694085 @default.
• W2158638287 hasConcept C2777240266 @default.
• W2158638287 hasConcept C2778239845 @default.
• W2158638287 hasConcept C2779422266 @default.
• W2158638287 hasConcept C2781187634 @default.
• W2158638287 hasConcept C2781413609 @default.
• W2158638287 hasConcept C526805850 @default.
• W2158638287 hasConcept C71924100 @default.
• W2158638287 hasConceptScore W2158638287C117643217 @default.
• W2158638287 hasConceptScore W2158638287C121608353 @default.
• W2158638287 hasConceptScore W2158638287C126322002 @default.
• W2158638287 hasConceptScore W2158638287C143998085 @default.
• W2158638287 hasConceptScore W2158638287C2776232967 @default.
• W2158638287 hasConceptScore W2158638287C2776256026 @default.
• W2158638287 hasConceptScore W2158638287C2776694085 @default.
• W2158638287 hasConceptScore W2158638287C2777240266 @default.
• W2158638287 hasConceptScore W2158638287C2778239845 @default.
• W2158638287 hasConceptScore W2158638287C2779422266 @default.

• next